Kelsey W. Nassar

Also affiliated with University of Colorado Anschutz Medical Campus

Biochemistry, Genetics and Molecular BiologyMedicineComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma”.

Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-1126

N/A

0DataRank · unranked

38 citations

Jennifer D. Hintzsche, Stacey M. Bagby, Veronica L. Espinoza, Christophe Langouët-Astrié, Carol M. Amato +6 more

Chemokine Receptor 1 and its associated immune pathway are downregulated in SF3B1 MT blood and non-blood cancers

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.31.485699

N/A

0DataRank · unranked

0 citations

Hyunmin Kim, Christina L. Paraggio, Claudia E. Leonard, Shanye Yin, Binkai Chi +11 more

Supplementary Tables and Figures from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma

Figshare(2023)10.1158/1535-7163.22521675.v1

N/A

0DataRank · unranked

0 citations

Jennifer D. Hintzsche, Stacey M. Bagby, Verónica Espinoza, Christophe Langouët-Astrié, Carol M. Amato +6 more